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CorrespondenceWhat Controls T Cell Receptor
Phosphorylation?
In a study published inCell, Xu et al. (2008)
raised the intriguing possibility that tyro-
sine residues present in the immunore-
ceptor tyrosine-based activation motifs
(ITAMs) of the cytoplasmic domain of the
CD33 subunit of the T cell receptor (TCR)
are sequestered in the membrane. Here,
they are inaccessible to tyrosine kinases
that would otherwise drive signaling.
As a consequence, the authors proposed
that ‘‘triggering’’ of the TCR—that is, the
events leading to phosphorylation of the
receptor—must be dependent upon
some, as yet undefined, process that
liberates the ITAMs from the membrane.
In an accompanying Preview, Kuhns and
Davis (2008) invoked the idea that mem-
brane association constitutes a ‘‘safety
catch’’ that prevents untoward triggering
of the TCR. Such effects add an additional
layer of complexity to the TCR triggering
problem.
Using equilibrium dialysis, Xu et al.
showed that the cytoplasmic domain of
CD33 (CD33CD) partitioned into acidic
rather than zwitterionic lipids. They then
went on to derive a structural model for
ITAMs bound by acidic lipids using
nuclear magnetic resonance (NMR)-
based methods. A new in vivo FRET-
based assay suggested that the associa-
tion of the ITAM with the membrane was
dependent on a cluster of positively
charged residues in the membrane-proxi-
mal amino-terminal region of CD33CD;
mutation of these residues reduced the
association of CD33CD with the mem-
brane as detected by the FRET assay.
The obvious question was, does mem-
brane association prevent kinases from
accessing ITAMs in vivo? Xu et al. showed
that the wild-type CD33 ITAM is not phos-
phorylated in resting T cells, implying that
it may indeed be completely inaccessible
to kinases. Somewhat surprisingly, how-
ever, they did not go on to clinch the argu-
ment by showing that therewas increased
phosphorylation of the membrane nonas-
sociating CD33CD mutant. The results
of this experiment turn out to be inconsis-
tent with the predictions of Xu and
colleagues.668 Cell 142, September 3, 2010 ª2010 ElseTo show that CD33CD is not phosphor-
ylated in resting Jurkat T cells, Xu et al.
used a chimeric protein consisting of
murine CD33CD fused to the extracellular
and transmembrane domains of the
human natural killer cell inhibitory recep-
tor KIR2DL3. We generated FLAG-tagged
forms of this protein and a second
chimera consisting of the extracellular
and transmembrane domains of KIR2DL3
fused with CD33CD mutated at the set of
clustered positively charged residues
proposed to mediate membrane asso-
ciation, that is, the mutant Emut1+2
described by Xu et al. (see Experimental
Procedures). We expressed the two
chimeras at similar levels in Jurkat
T cells using a lentivirus expression
system (Figure S1A) and probed for
phosphorylation of CD33CD by western
blotting (Figure S1B). Neither KIR2DL3/
CD33CD nor KIR2DL3/CD33CDEmut1+2
immunoprecipitated with anti-FLAG anti-
body showed detectable phosphorylation
in resting T cells (Figure S1B, lanes 1
and 2). Even after very long exposures of
the blots, we were unable to detect phos-
phorylation over background levels of
cross-reactivity of the antibody and we
saw no differences in signal for the wild-
type versus the mutant proteins (Fig-
ure S1B). This was also the case for
wild-type and Emut1+2-mutated forms
of full-length CD33 incorporated into the
TCR complex (data not shown).
These findings suggest either that
the Emut1+2 mutations do not release
the ITAMs from the membrane or that,
in vivo, the association with the mem-
brane is weaker than expected and
some other process prevents CD33CD
phosphorylation in resting cells. We sus-
pected that tyrosine phosphatases might
be responsible for the lack of phosphory-
lation of thewild-type andmutant forms of
CD33CD. To test this, we incubated cells
expressing the chimeric proteins with
the tyrosine phosphatase inhibitor, perva-
nadate (Swarup et al., 1982). Both the
wild-type and mutated forms of CD33CD
were heavily phosphorylated following
incubation of the cells for 20 min withvier Inc.the inhibitor (Figure S1B, lanes 3 and 4).
Time course experiments indicated that
rather than enhancing it, the Emut1+2
mutations somewhat slowed the kinetics
of CD33CD phosphorylation (data not
shown). In vivo, therefore, the wild-type
form of CD33CD seemed to be at least
as accessible to tyrosine kinases as
the mutated, membrane nonassociating
form of the protein when kinase activity
could be observed by inhibiting phospha-
tase activity. Finally, CD33was among the
more heavily tyrosine phosphorylated
proteins present in whole-cell lysates
from pervanadate-treated wild-type
Jurkat T cells (Figure S1C), emphasizing
its accessibility to kinases relative to other
kinase targets.
How can our observations be recon-
ciled with those of Xu et al.? Our experi-
ments suggest that membrane associa-
tion, if it occurs, has less impact on
CD33CD phosphorylation than might
have been expected on the basis of the
Xu et al. work. The strongest evidence for
lipid association is, of course, the NMR
structure of CD33CD stably bound to
acidic lipids. It should be borne in mind,
however, that we know little about the
actual distribution of inner leaflet
lipids around receptors embedded in the
membrane. Recent work by Zech et al.
(2009) shows that the acidic phospholipid
phosphatidylserine is enriched in mem-
brane sheets isolated from activated
T cells using beads coated with anti-CD3
antibodies, but the extent to which this
reflects the distribution of lipids in the
immediate vicinity of the TCR in resting
or activated cells is unclear. The density
or properties of the acidic lipids adjacent
to CD33 in resting cells might be insuffi-
cient to sustain an interaction of the type
demonstrated in vitrobyXuetal.Whatever
interaction ITAMs have with membranes
in vivo might be too weak and dynamic to
prevent access of the kinases.
The reasons for the low levelsofCD33CD
phosphorylation in resting T cells remain to
be fullyworkedout. Inanydiscussionof the
possible constraints on tyrosinephosphor-
ylation of the TCR, some consideration
must be given to the protein tyrosine phos-
phatases (PTPs) present at the cell surface,
such as CD45 (Hermiston et al., 2003).
Leukocytes express as many as 105 CD45
molecules, i.e., 2–3 for every TCR (Wil-
liams and Barclay, 1986), each with very
broad substrate specificity (Barr et al.,
2009); the catalytic activities of PTPs have
been estimated to be 10- to 1000-fold
higher than that of tyrosine kinases
(discussedby Fischer et al., 1991). Another
contributing factor is the activity of inhibi-
tory kinases such as Csk, which also
constrain T cell activation (Schoenborn
et al., 2009). Progress in understanding
TCR triggering will require the teasing
apart of these and other competing
factors and the identification of those
factors with the largest impact on net
phosphorylation of the TCR. The effects
of pervanadate on phosphorylation levels
in resting T cells observed by ourselves
(Figures S1B and S1C) and by others
many years ago (e.g., O’Shea et al., 1992)
suggest that PTPs could be key. For us,
the sheer weight of the numbers also
warrants their serious consideration.SUPPLEMENTAL INFORMATION
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Multilayered Control of T Cell
Receptor PhosphorylationWe would like to respond to the Corre-
spondence by Fernandes et al., but first
we will summarize the data in our Cell
paper (Xu et al., 2008). Our study used
a biophysical approach to examine the
binding of the CD33 cytoplasmic domain
(CD33CD) to the plasma membrane. We
reported a new FRET assay to examine
CD33CD binding to the inner leaflet of
the plasma membrane in live Jurkat cells,
a transformed T cell line. Furthermore, we
developed an approach to determine
the NMR structure of CD33CD bound in
a lipid bilayer environment. The structure
showed that the two tyrosines of the im-munoreceptor tyrosine-based activation
motif (ITAM) partitioned into the hydro-
phobic core of the bilayer in a dynamic
manner, with substantial movement of
the two tyrosines and other elements of
the cytoplasmic domain (Figure 6, Xu
et al., 2008). Microscopy data yielded
similar FRET values for CD33CD tagged
with C-terminal teal fluorescent protein
(TFP) and for a positive control in which
TFP was in close proximity to the plasma
membrane (there was a three amino acid
linker between the transmembrane and
TFP domains). These data indicated that
most of the cytoplasmic domain wasmembrane bound in these transfected
nonstimulated Jurkat cells. However, we
did not claim that all CD33 cytoplasmic
domains in a given T cell are completely
bound to the plasma membrane. This
would be impossible in a biological sys-
tem because binding events always
follow equilibrium conditions, with the
size of the bound versus free fractions
being determined by the ratio of on and
off rates. It follows that changes in equilib-
rium can result in dissociation of CD33CD
from the membrane. Our data showed
a structure with substantial mobility in
which changes in equilibrium, such as
recruitment of the tyrosine kinase Lck,
could enable phosphorylation.
We wish to point out that we did not
claim that binding of CD33CD to the
membrane was the only mechanism that
prevents spontaneous T cell signaling.
It is well established that there is
multilayered control of T cell receptor
(TCR) signaling because completeeptember 3, 2010 ª2010 Elsevier Inc. 669
